@article{3c0229b88a974337bf75cacc56f13408,
title = "Association of Primary Prophylactic (PP) Granulocyte-colony Stimulating Factor (G-CSF) Use with Chemotherapy Dose Modifications and Relative Dose Intensity (RDI) Among Breast Cancer Patients Receiving High-risk Regimens for Febrile Neutropenia (FN)",
abstract = " J. Shaw; J. Schenfeld; A. Balasubramanian; R. Jaramillo; D. Sandchafer; M. Kelsh ",
author = "Reshma Mahtani",
note = "314 Background: FN is a primary driver of chemotherapy modification and reduced RDI. Breast cancer patients often receive regimens with high risk ( > 20\%) for FN. PP G-CSF use is recommended to decrease incidence of infection, as manifested by FN. Real-world evidence describing the association of G-CSF with reduced RDI in breast cancer patients is lacking.",
year = "2021",
month = sep,
day = "21",
language = "American English",
volume = "39",
journal = "Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Quality Care Symposium",
}